Introduction
Since its discovery as a cytokine secreted from transformed fibroblasts with the ability to transform normal fibroblasts in vitro, transforming growth factor (TGF)-b has been intensively studied as a cytokine closely related to tumourigenesis. Although mounting evidence has unequivocally implicated TGF-b in tumourigenesis, it has also revealed TGF-b to have both tumour-suppressive and tumour-promoting roles, depending on the context of a cancer cell itself and the surrounding microenvironment, as reviewed by Derynck et al. (2001) ; Bierie and Moses (2006) ; Jakowlew (2006) ; Massague and Gomis (2006) and Pardali and Moustakas (2007) . Specifically, analyses of a series of transgenic mouse models, in which TGF-b was genetically engineered to be oversecreted at a specific stage of carcinogenesis, provided compelling evidence that TGF-b suppressed tumour growth during the early stages of tumour formation, whereas it accelerated tumour progression at later stages (Weeks et al., 2001; Muraoka-Cook et al., 2004) . Importantly, these experimental findings are consistent with circumstantial evidence of human tumours in vivo (see the above reviews), and TGF-b signalling is currently thought to be selectively perturbed during tumourigenic processes, thus resulting in attenuation of cell sensitivity to the antimitogenic effect of TGF-b and the changing cellular readout of signals from tumour suppressive to tumour promoting. Consequently, as one of the most potent promoters of tumour progression, TGF-b is a potential target for therapeutic intervention in the process, as well as hepatocyte growth factor, Notch, Wnt and Hedgehog signalling. Aiming at its applications in anticancer treatment, continuous efforts have to be made to better understand the molecular mechanisms underlying the tumour-promoting effects of TGF-b.
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases central to tumour invasion, metastasis, angiogenesis and malignant cell proliferation. MMP-10, also called stromelysin-2, constitutes a group with MMP-3 (stromelysin-1), both of which are closely related with regard to structure and substrate specificity. However, some differences in inducibility, activity and cellular distribution have been observed. In particular, expression of MMP-10 is seemingly restricted to epithelial cells in contrast to stromelysin-1, which is abundantly expressed in dermal fibroblasts (Windsor et al., 1993) . At a molecular level, MMP-10 potentially has a central function in an MMP activation cascade because of its ability to cleave several proMMPs including MMP-1, -7, -8, -9 and -13 (Nakamura et al., 1998; Ramos-DeSimone et al., 1999) . In tumour tissues, consistent with its epithelial-specific expression, MMP-10 is predominantly expressed in the tumour mass rather than the surrounding stromal fibroblasts, unlike several other MMPs that are predominantly found in tumour stroma (Kerkela et al., 2001; Impola et al., 2004) . Of note, MMP-10 expression is associated with malignant aggressiveness in various cancers (Mathew et al., 2002; Cho et al., 2004; Gill et al., 2004; Aung et al., 2006; Miyata et al., 2007) . Mechanistically, MMP-10 is considered to be involved in the remodelling of the extracellular matrix associated with growth and expansion of the neoplastic cell mass rather than metastatic potential (Kerkela et al., 2001; Cho et al., 2004; Impola et al., 2004) .
We studied a molecular pathway of TGF-b that meditates its protumourigenic effects and recently characterized the role of hepatocyte nuclear factor-4a in gene expression by TGF-b (Ishikawa et al., 2008) . In this study, we examined transcriptional induction of MMP-10 by TGF-b and discovered a critical function of myocyte enhancer factor (MEF)-2A and class IIa histone deacetylases (HDACs). In particular, TGF-b promoted acetylation and DNA binding of MEF2A, together with acetylation of core histones around the promoter, which were suggested to be causally associated with the degradation of HDACs facilitated by signalling.
Results

Involvement of MEF2A in MMP-10 induction by TGF-b
Transforming growth factor-b signalling targets expression of MMP-10. As shown in Figures 1a and b , MMP-10 was induced by TGF-b at mRNA and protein levels in both mouse and human mammary epithelial cell lines, NMuMG and MCF10A. Time course experiments indicated that until 6 h after treatment, the level of MMP-10 mRNA decreased to about one-third of the control and then began to increase, finally reaching nearly 10-fold after 24 h (Figure 1c ). The induction was completely abolished by cycloheximide, which implied the involvement of de novo protein synthesis (Supplementary Figure 1a) . A reporter assay using the promoter region of MMP-10, spanning from þ 11 to À886 bp (Chang et al., 2006) , suggested that induction was transcriptionally regulated. Luciferase activity from the reporter increased around 10-fold after 24 h of treatment with TGF-b, which was comparable with the proportional induction of mRNA. As in other TGF-bregulated gene expression, the Smad pathway was involved in the upregulation of MMP-10, as described below (Supplementary Figure 1c) , whereas the involvement of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase pathways was unlikely (data not shown).
Notably, we found that mutations in the MEF2 site within the promoter region markedly reduced the promoter response to TGF-b (Figure 1d ). This indicated that the MEF2 site was indispensable for transactivation of the MMP-10 promoter by TGF-b signalling, thus suggesting a role of a MEF2 family transcription factor in the induction. To address this possibility, we treated cells with small interfering RNA (siRNA) for MEF2 family transcription factors and examined the effect on (a) NMuMG cells were transfected with small interfering RNA (siRNA) for MEF2A (#1 and #2) or the negative control (Ctr; 100 nm) and were treated with 2 ng/ml TGF-b1 48 h later. After incubation for 24 h, the mRNA levels of MMP-10 and integrin-a5 were analysed by real-time reverse transcription (RT)-PCR as in Figure 1a . (b) Cells expressing Flag-tagged MEF2A and MEF2B, which were established by the retrovirus-mediated gene transfer method using a series of vectors of pMXs-IP (Materials and methods), were treated with 2 ng/ml TGF-b1 for 24 h. The mRNA level of MMP-10 was analysed by real-time RT-PCR as above. Expression of exogenous proteins was confirmed by immunoblotting using the antibody to the Flag tag. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is shown as a loading control. (c, d) Cells were transiently cotransfected with the wild-type MMP-10 promoter reporter plasmid and the pMXs-IP expression vectors for MEF2A and MEF2B (c) or Smad proteins (d) together with the phRL/CMV plasmid. The cells were then treated with TGF-b as described above. Reporter activities were evaluated as in Figure 1d . *Po0.05; **Po0.01. Expression of the Smad proteins was confirmed by immunoblotting using the antibody to the Flag tag. GAPDH is shown as a loading control. (e) Cells were infected by lentivirus encoding short hairpin RNA for Smad3 or the control as described in Supplementary Materials and methods. The knockdown effect was confirmed as shown in Supplementary Figure 1b Figure 2e ) of Smad3, the only Smad protein involved in MMP-10 induction as described below, showed a significant effect on transcription from the MEF2 site, although the up-and downward manipulations of the expression level were slightly inhibitory and stimulatory, respectively. These results suggested that Smad3 was not fundamentally involved in transactivation of the MEF2 site.
Acetylation and DNA binding of MEF2A stimulated by TGF-b DNA binding and/or transcriptional activity of MEF2A is regulated post-translationally by protein modification, including phosphorylation, acetylation and sumoylation, in response to various extracellular stimuli (Ornatsky et al., 1999; Kato et al., 2000; Ma et al., 2005; Shalizi et al., 2006) . Given the role of MEF2A in transactivation of MMP-10 by TGF-b, the signalling was expected to modify MEF2A and increase its transcriptional activity. We first examined the phosphorylation status of MEF2A in the presence and absence of TGF-b. However, it was unchanged (data not shown), consistent with another finding that MMP-10 induction by TGF-b was independent of p38 MAPK kinase and novel protein kinase C (PKCd and e; data not shown), which reportedly mediated MEF2A phosphorylation (Ornatsky et al., 1999; Yang et al., 1999; Zhao et al., 1999) . We then focused on acetylation, which positively regulates the DNA-binding ability of MEF2A (Ma et al., 2005; Angelelli et al., 2008) . When MEF2A was immunoprecipitated and analysed by immunoblotting with an antibody specific to acetylated lysine, the signal was significantly augmented by TGF-b (Figure 3a) . Similarly, binding of MEF2A to the promoter region of the MMP-10 gene, which was evaluated by chromatin immunoprecipitation assay, was increased (Figure 3b ). Binding of MEF2A to a region distal to the promoter was unaltered under the same conditions.
Together, these results suggested that TGF-b signalling stimulates acetylation of MEF2A, thus resulting in its increased binding to the site of the MMP-10 promoter and eventual upregulation of the gene.
Downregulation of class IIa HDACs and their involvement in MMP-10 induction by TGF-b
It has been well established that MEF2 is bound to class IIa HDACs directly (Figure 4a ; Miska et al., 1999; Sparrow et al., 1999; Lemercier et al., 2000) and that MEF2-dependent transcription is negatively regulated by HDACs in some genes. To test whether the MMP-10 promoter was also under the negative influence of HDACs, we examined the effect of siRNAs for the class IIa HDACs, HDAC4, 5 and 7 (Supplementary Figure  2d) , on MMP-10 mRNA expression. In fact, in the vascular endothelium during early development of mice, MMP-10 expression was constitutively downregulated by HDAC7 (Chang et al., 2006) . Introduction of each siRNA for HDACs into the cells increased the basal level of MMP-10 expression to some extent in unstimulated conditions (Figure 4b ). When siRNAs for the three class IIa HDACs were introduced together, a more prominent effect was observed; MMP-10 expression was elevated to a level comparable with that obtained by TGF-b treatment. In contrast, when HDACs were exogenously overexpressed by a Tet-Off system (Figure 4c ; Dox À), TGF-b-mediated MMP-10 induction was diminished. The transcriptional response of the MMP-10 promoter was also reduced (Figure 4d) . These results together supported the inhibitory role of class IIa HDACs in MMP-10 transactivation from the MEF2 site. Basically, the expression of class IIa HDAC suppressed TGF-b-stimulated acetylation (Figure 4e ). It is noteworthy that the class I HDAC, HDAC3, even if overexpressed, did not inhibit MMP-10 mRNA induction or transcriptional activity of the reporter ( Figures  4c and d) , thus proving the specificity of the effects of class IIa HDACs and excluding the nonspecific effects of overexpression of HDACs.
The negative impact of HDACs on MMP-10 expression implied that TGF-b signalling somehow circumvented the effect of HDACs to transactivate MMP-10. We approached this issue by examining the behaviour (Figure 5a ). Under the same conditions, their mRNA levels were rather increased (Supplemetary Figure 2d ; Ctr, TGF-b À/ þ ), and more critically, protein levels of exogenously expressed class IIa HDACs decreased as their endogenous counterparts did, thus suggesting that degradation of HDAC proteins was facilitated by TGF-b signalling (Figure 5b ). It is noteworthy that it was not until 8 h that the process became apparent (Figure 5c ), which correlates well with MMP-10 mRNA induction (Figure 1c ). In the presence of MG132 or lactacystin, a proteasome inhibitor, decrease in the protein levels was attenuated, thus suggesting that the process was proteasome-dependent ( Figure 5d ). In general, degradation of proteins through proteasome requires ubiquitination of a target protein, which is mediated by E3 ubiquitin ligases. In TGF-b signalling, several E3 ligases have been identified to target Smads, SnoN/c-Ski and the type I TGF-b receptor, thereby contributing to signal transduction (reviewed by Izzi and Attisano, 2004; Inoue and Imamura, 2008) . In our previous DNA microarray analysis, a subset of E3 ligases was found to be upregulated by TGF-b treatment in the cell line (data not shown). In this study we tested the role of these E3 ligases, including WWP1, 2, Nedd4, After 24 h, cells were lysed, and luciferase activities were assessed using the dual luciferase assay kit. *Po0.05; **Po0.01. (e) Tet-Off cells expressing the Flag-tagged HDAC4, established as described in panel c, were treated with TGF-b in the presence or absence of 10 ng/ml Dox and processed for immunoprecipitation followed by immunoblotting with anti-MEF2A antibodies and acetylated lysine similar to Figure 3a .
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Arkadia and Smurf1 and 2, in proteasome-dependent degradation of HDACs by knockdown with siRNA. However, none of the siRNAs for these E3 ubiquitin ligases showed the expected effect of suppression of MMP-10 expression under TGF-b signalling (data not shown). In summary, the results suggest that TGF-b facilitates degradation of class IIa HDACs in a proteasomedependent manner, thus resulting in the removal of the negative effect of HDACs on transcriptional activity of MEF2A; this further contributes to MMP-10 transactivation.
Involvement of Smad3 in MMP-10 induction by TGF-b
Next, we examined the involvement of Smads in MMP-10 induction using a lentiviral-mediated short hairpin RNA system (Supplementary Figure 1b) . Among Smads, knockdown of Smad3 alleviated induction, whereas that of Smad2 and 4 had virtually no effect (Supplementary Figure 1c) . These results indicated that MMP-10 was a target of the Smad pathway, although this was independent of Smad4. Induction of integrin-a5 was decreased by knockdown of Smad3 and 4 (Supplementary Figure 1c) .
To define the role of the Smad pathway in TGF-binduced MMP-10 expression, we focused on its relationship with transcriptional activation of MEF2A and degradation of class IIa HDACs, the events critical for the induction as described above. In a previous report, it was suggested that Smad2 directly interacted with MEF2A in the myoblasts and enhanced transcriptional activity (Quinn et al., 2001) . Thus, Smad3, instead of Smad2, may have interacted with MEF2A and activated transcription in epithelial cells. However, the interaction between Smad3 and MEF2A was not detected, with or without TGF-b, 2 or 24 h after stimulation in mammary epithelial cells (Supplementary Figure 3a) . Interaction of Smad2 or 3 with Smad4, which served as a positive control for the interaction, was detected 2 h after stimulation with TGF-b (Supplementary Figure 3a) , thus suggesting that in the epithelial cells, Smad3 did not physically interact with MEF2A. Another possibility was that Smad3 affected transcriptional activity of the MEF2 site in an indirect way, for example, by somehow promoting (coactivators) or interfering with (corepressors) recruitment of transcriptional cofactors onto the promoter. However, these possibilities are unlikely, because neither expression nor knockdown of Smads, including Smad3, had any significant influence on transcription dependent on the MEF2 site in the reporter assay, as mentioned above (Figures 2d and e) . Together with an additional observation that the induction of MMP-10 by TGF-b was further severely impaired by double knockdown of Smad3 and MEF2A (Supplementary Figure 1d) , the findings consistently suggested that the role of Smad3 was independent of that of MEF2A. Incidentally, subcellular localization of MEF2A, which was exclusively nuclear, was unaltered during TGF-b stimulation.
Alternatively, it was plausible that Smad3 physically or functionally interacted with class IIa HDACs and somehow contributed to the degradation of the HDACs, thereby having a positive role in MMP-10 induction. In this case, knockdown of Smad3 was expected to interfere with degradation of HDACs, thereby maintaining the levels of HDACs. We tested this possibility with HDAC9, which appeared most extensively degraded under TGF-b signalling, and found that TGF-b decreased the HDAC9 protein in the knockdown condition of Smad3 as efficiently as in the control, thus suggesting that the role of Smad3 was unrelated to HDAC degradation (Supplementary Figure 3b) . The reason for the decrease in the basal level of the HDAC9 protein by Smad3 knockdown is not known.
Change in acetylation level of core histones in the promoter region of the MMP-10 gene under TGF-b signalling Acetylation of N-terminal tails of core histones, which weakens electrostatic interactions between positively charged histone tails and negatively charged DNA, relaxes chromatin structure and consequently facilitates recruitment of transcription factors to DNA target sequences. Accordingly, the status is associated with transcriptional activity; in general, an increased level of histone acetylation is the hallmark of increased transcriptional activity. To substantiate the involvement of HDAC activity in MMP-10 transactivation and its removal by TGF-b, we addressed the acetylation status of core histones, H3 and H4, around the MEF2 site in the MMP-10 promoter by chromatin immunoprecipitation using antibodies specific to acetylated H3 and H4. Figure 6a shows that TGF-b treatment significantly elevated H3 and H4 acetylation in the region surrounding the MEF2 site but not that in the region distal to the promoter. Importantly, elevated acetylation around the site was specifically suppressed by enforced expression of class IIa HDAC, even by HDAC4 whose effect observed in the other assays was relatively weak compared with others. This observation was consistent with a negative role of HDACs on the MMP-10 promoter activity (Figure 6b ; Dox ), emphasizing the significance of HDAC degradation on TGF-b stimulation in MMP-10 transactivation.
Discussion
Transcriptional regulation of MMP-10 by TGF-b signalling Expression of most MMPs is normally low in tissues and is induced where and when the extracellular matrix is actively remodelled. In general, their expression is primarily regulated at the transcriptional level as a target downstream of immediate-early response genes of transcription factors, while there is also evidence of post-transcriptional regulation (Chakraborti et al., 2003; Clark et al., 2008) . In fact, cis-acting elements to which the gene products bind have been found in the MMP promoters. In the MMP-10 promoter, TATA boxes at around À30 bp are accompanied by activator protein-1 sites around 70 bp as in those of other MMPs such as MMP1, 3, 7, 9 and 13. In these promoters, the promoter-proximal activator protein-1 site is a major mediator of signalling of several growth factors and cytokines (Chakraborti et al., 2003; Clark et al., 2008) .
In this study, we investigated TGF-b-mediated transactivation of MMP-10 and addressed a novel TGF-b signalling pathway, dependent on the degradation of class IIa HDACs and activation of MEF2A. Unlike other cytokines that signal through the activator protein-1 site, TGF-b signals through the MEF2A site by stimulating acetylation of MEF2A, which is accompanied by increased DNA binding. It is noteworthy that this event is coupled with degradation of class IIa HDACs, which directly interact with MEF2A and suppress its transcriptional activity. As shown in Figure 7 , the most likely scenario is that degradation of HDACs is stimulated under TGF-b and triggers a sequential event; that is, release of MEF2A from HDACs, followed by its association with coactivators such as p300 with acetylase activity and an increase in MEF2A acetylation, as well as that of core histones, thus resulting in eventual activation of transcription from the MEF2 site. -+ -+ -+ * * * * * * * Figure 6 Transforming growth factor (TGF)-b elevates acetylation levels of core histones on the matrix metalloproteinase (MMP)-10 promoter region. (a) NMuMG cells treated with 2 ng/ml TGF-b for 24 h were lysed after fixation with 1% formaldehyde. The lysates were sonicated and subjected to chromatin immunoprecipitation with control or anti-histone H3 or H4 antibodies, as described in Materials and methods section. Acetylation of the core histones H3 (AcH3) and H4 (AcH4) on the MMP-10 promoter was quantified by real-time reverse transcription (RT)-PCR using specific primers amplifying the indicated loci. PCR was performed in triplicate, and at least three independent samples were examined. Bars represent averages (%) ± s.d. normalized to input. (b) Tet-Off cells expressing the Flag-tagged HDAC4, established as described in Figure 4c , were treated with TGF-b in the presence or absence of 10 ng/ml Dox, and the lysates were subjected to chromatin immunoprecipitation as in panel a. *Po0.05.
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Involvement of MEF2 and class IIa HDACs in the regulation of MMP-10 expression was previously reported in vivo in the vascular endothelium of the early developmental stages of mice (Chang et al., 2006) . In the tissue of the particular developmental stage, MMP-10 expression was constitutively repressed to prevent its inappropriate activation and downstream programming, which would lead to abnormal vascular remodelling. Mechanistically, this was achieved by interaction of MEF2 with HDAC7 on the MMP-10 promoter. As demonstrated in this case, previous studies have implicated class IIa HDACs in MEF2 regulation. This study is the first to characterize the interplay between the two in gene expression under TGF-b signalling. In terms of the molecular mechanism of how MEF2 transcriptional activity is controlled by HDACs, studies on calcium signalling, where MEF2 has emerged as an integrator linking the signalling to gene expression, have provided substantial knowledge (McKinsey et al., 2002) . In the signalling, calcium/calmodulin-dependent protein kinases (CaMK) are central players and increase the transcriptional activity of MEF2A and C by disrupting MEF2-HDAC interactions. In this case, CaMK phosphorylates MEF2 at specific sites and then chaperone protein 14-3-3 docks on these sites, which disrupts HDAC-MEF2 complexes and further accelerates the export of HDACs into the cytoplasm. In TGF-b signalling, the negative impact of HDACs is removed by specifically promoting degradation of HDACs dependent on proteasome activity without discernable alteration of the localization. This is in contrast to CaMK signalling in which the nuclear export of HDACs directed by 14-3-3 has a major role.
Alternative or additional mechanisms could be operating under TGF-b signalling to release MEF2A from HDACs and/or activate MEF2A. In comparison with previous findings (Quinn et al., 2001; Liu et al., 2004; Kang et al., 2005) , Smad3 may bind MEF2A and potentiate transcription. It might also disrupt the interaction between MEF2A and HDACs, or directly or indirectly promote the interaction of MEF2A with coactivators. As described above, largely based on the results in Figures 2d and e, and Supplementary Figures  1c, d and 3 , such a role of Smad3 is unlikely in MMP-10 transactivation through the MEF2 site under TGF-b signalling. Presumably, Smad3 exerts its effect directly or indirectly through another element distal to the promoter outside the upstream region studied in this study. In contrast to Smad3, Smad2 and 4 did not appear to have a role in transactivation (Supplementary Figure 1c) . As for Smad4, we confirmed the results by silencing the protein with siRNA, obtaining similar results to those with short hairpin RNA (data not shown). Thus, the induction of MMP-10 by TGF-b was dependent on Smad3, but not on Smad2 or 4. Previous studies have shown that Smad proteins have unique roles in gene expression under TGF-b signalling with distinct transcriptional targets (Derynck et al., 1998; Piek et al., 2001; Levy and Hill, 2005) .
To develop therapeutic methods to inhibit tumourpromoting effects of TGF-b, a comprehensive understanding of the molecular signatures of the two opposing effects of TGF-b, tumour-suppressing and tumour-promoting, is essential, and identification of a signalling cascade that specifically engages in its tumourpromoting activity is the first key step. Recent efforts in this direction have revealed increasing diversification of the signalling cascades of TGF-b downstream of Smads. In one such branch, which is driven by HMGA2, the signalling is propagated further down by repressors for E-cadherin, such as Snail, Slug, Twist and Id2 (Thuault et al., 2006) . We recently identified hepatocyte nuclear factor-4a as an additional downstream effector of HMGA2 that has a role in regulating expression of a subset of TGF-b-inducible genes such as Tenascin C and a tissue inhibitor of metalloproteinase 3 (Ishikawa et al., 2008) . Given a possible further expansion of the cascades and mediators of TGF-b signalling, it seems strategically necessary to focus on the major contributors to poor prognosis as particular targets and their regulatory cascades in the signalling network. Such targets are probably varied among individual cancer cases. Our results will possibly contribute to specific blockage of such regulatory cascades that are dedicated to potential therapeutic targets of Tenascin C and MMP-10, thereby providing personalized medicine for cancer treatment.
Materials and methods
Cell culture and TGF-b treatment Mammary epithelial cell lines were obtained from the American Type Cell Collection. NMuMG mouse mammary epithelial cells were maintained as described previously (Kanome et al., 2007) . MCF10A human mammary epithelial cells were cultured in Dulbecco's modified Eagle's medium/ F-12 1:1 mixture (Invitrogen, San Diego, CA, USA) supplemented with 5% horse serum (Invitrogen), 20 ng/ml epidermal growth factor (Wako Pure Chemical Industries, Osaka, Japan), 10 mg/ml insulin (Wako), 0.5 mg/ml hydrocortisone (Sigma, St Louis, MO, USA), 100 U/ml penicillin and 50 mg/ml streptomycin. Cells were treated with 2 ng/ml TGF-b1 (R&D Systems, Minneapolis, MN, USA) in conditioned medium for the indicated time periods. MG132 and lactacystin (Calbiochem, San Diego, CA, USA) were pretreated 30 min before TGF-b1 treatment.
Expression plasmids
Retrovirus expression vectors, pMXs-IP and pMXs-IN, were constructed as described previously (Kitamura et al., 2003) . MEF2A cDNA was amplified from the NMuMG cDNA library, and MEF2B and HDACs cDNA were amplified from the mouse 17-day embryo marathon-ready cDNA library (Clontech, Palo Alto, CA, USA). cDNA was inserted into the pMXs-IP vector with Flag tag. Flag-tagged mouse Smads cDNA was kindly gifted from Dr K Miyazono (University of Tokyo, Tokyo, Japan), and this was inserted into the pMXs-IP vector. Tetracycline-controlled transcriptional activator (tTA) advanced/pMXs-IN was constructed by introducing the gene encoding tTA into pMXs-IN. The tetracycline-regulated retroviral expression vector pSIN-TRE II was a derivative of RNAi-Ready pSIREN-RetroQ-TetP (Clontech). It was constructed by replacing the puromycin N-acetyltransferase gene (Pur r ) driven by the phosphoglycerate kinase and TREmod/U6
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